Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0E4JU
|
|||
| Former ID |
DNC011661
|
|||
| Drug Name |
N-Hydroxy-N-methyl-3-naphthalen-2-yl-acrylamide
|
|||
| Synonyms |
CHEMBL63882; N-Hydroxy-N-methyl-3-naphthalen-2-yl-acrylamide; BDBM50015178; ZINC26247459; N-Methyl-N-hydroxy-2-naphthaleneacrylamide; (E)-N-hydroxy-N-methyl-3-(naphthalen-2-yl)acrylamide; (E)-3-(2-Naphthalenyl)-N-methyl-2-propenehydroxamic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H13NO2
|
|||
| Canonical SMILES |
CN(C(=O)C=CC1=CC2=CC=CC=C2C=C1)O
|
|||
| InChI |
1S/C14H13NO2/c1-15(17)14(16)9-7-11-6-8-12-4-2-3-5-13(12)10-11/h2-10,17H,1H3/b9-7+
|
|||
| InChIKey |
CORKVTFWNIPMDF-VQHVLOKHSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Arachidonate 5-lipoxygenase (5-LOX) | Target Info | Inhibitor | [1] |
| BioCyc | Aspirin-triggered lipoxin biosynthesis | |||
| Resolvin D biosynthesis | ||||
| Leukotriene biosynthesis | ||||
| Lipoxin biosynthesis | ||||
| Aspirin triggered resolvin D biosynthesis | ||||
| Aspirin triggered resolvin E biosynthesis | ||||
| KEGG Pathway | Arachidonic acid metabolism | |||
| Metabolic pathways | ||||
| Serotonergic synapse | ||||
| Ovarian steroidogenesis | ||||
| Toxoplasmosis | ||||
| NetPath Pathway | IL4 Signaling Pathway | |||
| Pathwhiz Pathway | Arachidonic Acid Metabolism | |||
| WikiPathways | Vitamin D Receptor Pathway | |||
| Arachidonic acid metabolism | ||||
| Eicosanoid Synthesis | ||||
| Selenium Micronutrient Network | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | In vivo characterization of hydroxamic acid inhibitors of 5-lipoxygenase. J Med Chem. 1987 Nov;30(11):2121-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.